The quest for longevity has long been a topic of interest in the scientific community, with researchers exploring various interventions that could potentially extend lifespan. One such intervention that has garnered attention is the use of rapamycin, a molecule that has been touted as a potential anti-ageing drug. However, recent reanalysis of data has cast doubt on the efficacy of rapamycin and other interventions such as fasting in extending lifespan.
A study conducted in 2025 analyzed data from 167 research papers across eight non-human species, including fish, mice, rats, and rhesus monkeys. The results initially suggested that animals given rapamycin or subjected to calorie restriction lived longer on average, leading researchers to believe that similar benefits could be seen in humans. However, a closer look at the data revealed that the benefits of these interventions were highly variable among individual animals.
According to Tahlia Fulton from the University of Sydney, the benefits of rapamycin and dietary restriction in extending lifespan are more like a lottery, with some individuals experiencing significant increases in lifespan, while others see minimal to no benefits. This variability means that there is no guarantee that these treatments will increase an individual’s lifespan, turning the quest for longevity into somewhat of a gamble.
The ultimate goal of longevity interventions, as explained by Fulton, is to “square the curve” of a graph showing population size versus lifespan. This would mean that more people would live longer, rather than just a select few. However, the latest research suggests that neither rapamycin nor dietary restriction achieves this goal, highlighting the need for further research to determine who benefits most from these interventions.
Matt Kaeberlein from the University of Washington raises an important point about the impact of longevity interventions on “healthspan inequality,” emphasizing the need to consider not just lifespan but also the quality of life in old age. Rapamycin, originally developed as an immunosuppressant for organ transplant patients, works by blocking the action of the mTOR protein, which plays a key role in cell growth and division. At low doses, it has shown promise in extending lifespan in animals by potentially protecting against DNA damage.
In conclusion, while the potential benefits of rapamycin and other longevity interventions are intriguing, the variability in outcomes among individuals underscores the need for further research to fully understand their effects. As expectations are tempered and more studies are conducted, researchers hope to tailor interventions to individual genetic codes and life experiences to maximize the chances of living a long and healthy life.
